Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) will report its 2020 financial results and corporate updates on April 15, 2021, with a conference call at 8:30 a.m. EDT. Investors can join via phone or webcast, accessing the call with specific dial-in numbers and a conference ID.

Affimed is focused on immuno-oncology, leveraging its proprietary ROCK® platform to develop therapies aimed at treating various tumors. The company aims to empower patients' innate immunity to combat cancer effectively.

Positive

• Upcoming release of 2020 financial results may provide investors with insights into company performance.
• Affimed's innovative ROCK® platform shows potential for advancing cancer treatment.

Negative

• None.

Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2020 results and corporate update on Thursday, April 15, 2021. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

The conference call will be available via phone and webcast. To access the call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 4271307 approximately 15 minutes prior to the call.

To access the live audio webcast of the conference call please visit the “Investors” section of the company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact

Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel: +1 (917) 436-8102

FAQ

When will Affimed release its 2020 financial results?

Affimed will release its 2020 financial results on April 15, 2021.

What time is the Affimed conference call scheduled?

The Affimed conference call is scheduled for 8:30 a.m. EDT on April 15, 2021.

How can I access the Affimed conference call?

To access the Affimed conference call, you can dial +1-646-741-3167 for U.S. callers and +44 (0) 2071 928338 for international callers.

What platform does Affimed use for its cancer therapies?

Affimed uses its proprietary ROCK® platform to develop cancer therapies targeted at various tumors.

Where can I find the webcast for the Affimed conference call?

You can find the webcast for the Affimed conference call in the 'Investors' section of the company's website.